OPKO Health, Inc. (NYSE: OPK)
announced today that GeneDx was invited to participate in the Molecular
Medicine Tri-Conference 2016, being held at the Moscone North Convention
Center in San Francisco, California from March 6th - 11th,
2016, and will also be exhibiting at Booth 606.
Wendy Chung, M.D. Ph.D., Associate Professor of Pediatrics and Medicine,
Columbia University and Chief Scientific Officer, GeneDx, will
participate in the session entitled PERSONALIZED DIAGNOSTICS, WHOLE
EXOME SEQUENCING AS A DIAGNOSTIC TOOL. Dr. Chung's presentation,
entitled The Future Use of Exome Sequencing as the Genetic Test of
Choice for Clinical Diagnostics, will take place on Monday, March
7th at 3:10 PM PST.
In her talk, Dr. Chung will review the experience of using whole exome
sequencing in clinical diagnostics for a wide range of genetic
conditions including technical improvements of the test over time, the
clinical yield of testing by indications, and the clinical utility in
testing for patient care both in the present and in the future regarding
how the test is likely to be used as a first line clinical test for all
Robert D. Daber, Ph.D., Vice President of Genomic Operations and Cancer
Genetics at GeneDx will be chairing both the GENOMIC SAMPLE PREP AND
BIOMARKER ASSAY DEVELOPMENT, EMERGING SAMPLE PREP TECHNOLOGIES FOR
GENOMICS APPLICATIONS and NOVEL CANCER BIOMARKER FFPE-BASED ASSAYS
sessions on Monday, March 7th.
Dr. Daber will also be presenting two talks. His first presentation, in
the EMERGING SAMPLE PREP TECHNOLOGIES FOR GENOMICS APPLICATIONS session
and entitled Eliminating Barriers to Precision Diagnostics: Cost,
Content, Turn-Around Time and Sample Size, will take place on
Monday, March 7th at 12:00 PM PST.
In his talk, Dr. Daber will discuss the potential NGS has for disrupting
routine clinical practice in many areas of medicine and the challenges
that have to be addressed to see that potential fulfilled. As many
health care practices look to build precision medicine programs, access
to clinical NGS testing for every patient is currently limited by
several challenges - including assays cost, turnaround time, test
sensitivity and actionable reporting of variants.
Dr. Daber's second talk, in the CELL-FREE DNA AND RNA ASSAYS session,
entitled Best Practices for Fusion Detection by Targeted RNA
Sequencing: Pre-Analytical Considerations, Assay Validation and More,
will occur on Wednesday, March 9th at 3:00PM PST.
In this talk, Dr. Daber will discuss the challenges and benefits of NGS
based targeted RNA sequencing in the detection of gene fusion events,
including nucleic acid isolation, sample preparation and downstream data
Andreas Matern, Vice President Collaborations and Innovation, GeneDx,
will be chairing a panel discussion in the TRANSLATIONAL RESEARCH
session entitled Inspiring Others to Innovate with Technology on
Tuesday, March 8th at 3:10PM PST, and presenting in the
INTEGRATED INFORMATICS DRIVING TRANSLATIONAL RESEARCH & PRECISION
MEDICINE, CONVERGENCE OF LARGE POPULATION & PERSONAL DATA FOR PATIENT
CARE, CLINICAL TRIALS & R&D session.
Mr. Matern's talk, entitled Innovation from the Clinical Laboratory -
The New Role of -Omics-Based Testing and Decision Support, will take
place on Wednesday, March 9th at 12:00PM PST.
In his talk, Mr. Matern will discuss how clinical laboratories are
changing beyond the simple "send sample, give us results" paradigm to an
information-driven ecosystem, working in close partnership with
providers, pharmaceutical companies, and hospitals to leverage the
knowledge they have accumulated to drive new medical discoveries and
improve patient care and outcomes. The emphasis will be on
bioinformatics, the combination of large data sets, and building systems
that work across multiple stakeholders and groups.
About OPKO Health, Inc.:
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation's third-largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore® prostate cancer test and the Claros®1
in-office immunoassay platform. Our pharmaceutical business features
Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched by
partner Tesaro, IV formulation in Phase 3). Our biologics business
includes hGH-CTP, a once-weekly human growth hormone injection (in Phase
3 and partnered with Pfizer), and a long-acting Factor VIIa drug for
hemophilia (entering Phase 2a). We also have production and distribution
assets worldwide, multiple strategic investments and an active business
development strategy. More information is available at www.opko.com.
GeneDx is a world leader in Genomics with an acknowledged expertise
in rare and ultra rare genetic disorders, as well as one of the broadest
menus of sequencing services available among commercial laboratories.
GeneDx provides testing to patients and their families in more than
55 countries. To learn more, please visit www.genedx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160224005776/en/
OPKO Health, Inc.
Carly Erickson, 202-600-4558
Terry Rooney, 212-223-0689
Source: OPKO Health, Inc.
News Provided by Acquire Media